S

Stereotaxis Inc
AMEX:STXS

Watchlist Manager
Stereotaxis Inc
AMEX:STXS
Watchlist
Price: 2.29 USD 1.33%
Market Cap: 193.9m USD
Have any thoughts about
Stereotaxis Inc?
Write Note

Stereotaxis Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Stereotaxis Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
S
Stereotaxis Inc
AMEX:STXS
Cash & Cash Equivalents
$10.7m
CAGR 3-Years
-36%
CAGR 5-Years
-20%
CAGR 10-Years
2%
Becton Dickinson and Co
NYSE:BDX
Cash & Cash Equivalents
$1.7B
CAGR 3-Years
-9%
CAGR 5-Years
26%
CAGR 10-Years
-1%
Boston Scientific Corp
NYSE:BSX
Cash & Cash Equivalents
$2.5B
CAGR 3-Years
9%
CAGR 5-Years
55%
CAGR 10-Years
26%
Stryker Corp
NYSE:SYK
Cash & Cash Equivalents
$3.9B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
11%
Abbott Laboratories
NYSE:ABT
Cash & Cash Equivalents
$7B
CAGR 3-Years
-9%
CAGR 5-Years
11%
CAGR 10-Years
7%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash & Cash Equivalents
$2.4B
CAGR 3-Years
21%
CAGR 5-Years
20%
CAGR 10-Years
17%
No Stocks Found

Stereotaxis Inc
Glance View

Market Cap
194m USD
Industry
Health Care

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The company is headquartered in St. Louis, Missouri and currently employs 130 full-time employees. The company went IPO on 2004-08-12. The firm's robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Its primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. The firm also offers to its customers the Stereotaxis Imaging Model S X-ray System and other accessory devices. The Genesis RMN System is designed to enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. The Odyssey Solution consolidates lab information onto an integrated display, enabling physicians to view and control all the key information in the operating room.

STXS Intrinsic Value
1.41 USD
Overvaluation 39%
Intrinsic Value
Price
S

See Also

What is Stereotaxis Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
10.7m USD

Based on the financial report for Sep 30, 2024, Stereotaxis Inc's Cash & Cash Equivalents amounts to 10.7m USD.

What is Stereotaxis Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
2%

Over the last year, the Cash & Cash Equivalents growth was -52%. The average annual Cash & Cash Equivalents growth rates for Stereotaxis Inc have been -36% over the past three years , -20% over the past five years , and 2% over the past ten years .

Back to Top